ABNM Nuclear Medicine common mistakes
ABNM Nuclear Medicine · Understand the traps and how to avoid them.
The candidate uses exposure, absorbed dose, equivalent dose, and effective dose interchangeably, and applies inverse-square falloff to an internally deposited beta-emitting radionuclide.
Radiation safety review often emphasizes external point sources, so candidates carry external-source intuition into internal dosimetry questions and rely on unit names rather than definitions.
What to do instead
Before answering, classify the source as external or internal. For external point sources, use inverse-square and shielding; for internal emitters, calculate absorbed dose in Gy from energy deposited per mass, and use committed effective dose in Sv with tissue weighting. Write the unit next to every number and reject any answer whose unit does not match the question.
When a stem gives calibration activity, administration time, and biologic excretion, the candidate decay-corrects with the physical half-life instead of the effective half-life and reports the result without checking units.
Half-life problems are usually practiced with physical half-life alone; candidates memorize A=A0(1/2)^n but forget that biologic clearance shortens the retained activity and that mCi must be converted to MBq when the answer choices require it.
What to do instead
Use a three-line ledger: A0, elapsed time, and the correct half-life. If biologic half-life is stated, calculate Teff=(Tp×Tb)/(Tp+Tb) before decay correction. Convert activity and time to consistent units, and sanity-check that the answer is less than A0 and greater than the physical-decay-only value.
The candidate attributes the localization of common radiopharmaceuticals to the wrong mechanism, such as assigning MAA to the reticuloendothelial system or expecting sulfur colloid to clear through renal tubular secretion.
Agents are often memorized by name and scan appearance rather than by mechanism, and similarly named kits make it easy to swap capillary blockade, phagocytosis, tubular secretion, and hepatocyte transport.
What to do instead
Build and rehearse a one-page table with columns for agent, mechanism, normal biodistribution, route of excretion, and common pitfalls. For example, MAA is trapped by pulmonary capillary blockade, sulfur colloid is taken up by phagocytes, MAG3 is secreted by renal tubules, and HIDA is transported by hepatocytes.
The candidate assumes the label activity equals the injected activity, assays a syringe in the dose calibrator without controlling geometry, and ignores residual activity left in the vial or tubing.
Clinical workflow often uses predetermined doses and shortcuts, while exam questions isolate variables such as calibration time, residual volume, and assay geometry.
What to do instead
Measure the syringe before and after administration, subtract the residual, and decay-correct to the actual injection time. Use a consistent, validated geometry and dilution when the activity is high. Know that dose calibrator accuracy is generally expected within about ±10%, and state the correction explicitly in calculations.
The candidate labels a ring artifact as patient motion, or calls a star artifact a detector calibration problem, and recommends repeating the acquisition instead of naming the correct quality-control check.
Artifacts look similar on low-resolution images, and candidates memorize artifact names without linking each pattern to its physical cause.
What to do instead
Map each artifact to a cause before choosing a next step: ring artifact suggests detector, collimator, or photomultiplier-tube calibration problems; star artifact suggests a high-count point source; motion produces blurring or duplicated edges; truncation means the body part is outside the field of view. Name one confirmatory QC step, such as collimator inspection, detector uniformity flood, or repeat acquisition with motion control.
The candidate interprets a solitary focal bone-scan lesion as metastasis without correlating prior imaging, radiographs, or SPECT/CT, and without considering trauma, artifact, or benign bone disease.
Pattern recognition rewards calling any focal uptake abnormal, but examination stems often test whether the candidate can avoid overcalling a single lesion and can recommend the appropriate correlation.
What to do instead
Use a structured read: image quality, biodistribution, lesion description, and clinical correlation. For a solitary bone lesion, state the differential and recommend radiograph or CT, with SPECT/CT when available. Treat the scan as one piece of evidence, not a diagnosis.
The candidate compares SUVmax values from PET scans obtained at different uptake times or blood glucose levels as if SUV were an absolute, protocol-independent measurement.
Software reports SUV automatically, so candidates forget the formula and the effects of body-size normalization, plasma glucose, insulin, partial volume, and scan timing.
What to do instead
Know that SUV is activity concentration divided by injected dose normalized to a body-size metric, and that the metric must be specified. Compare only same-protocol scans, check uptake time and glucose, and remember that small lesions underestimate SUV because of partial volume. Use SUV as supporting evidence, not as a standalone diagnosis.
The candidate calls symmetric supraclavicular or neck uptake on FDG PET metastatic disease rather than brown adipose tissue, or calls focal bowel uptake malignant without CT correlation.
FDG is not tumor-specific, and symmetric normal variants are easy to overcall when the candidate focuses only on intensity and ignores pattern, CT attenuation, and clinical context.
What to do instead
Learn normal-variant patterns: brown fat is typically symmetric and supraclavicular, axillary, or paraspinal; muscle uptake follows recent exertion or insulin; bowel uptake is often linear and corresponds to bowel on CT. Use CT correlation and clinical history, and consider warming or dietary preparation only when appropriate.
For radioiodine therapy, the candidate proceeds without a documented pregnancy test, does not address lactation, and manages thyroid hormone withdrawal or antithyroid medication in a way that is inconsistent with the stated protocol.
Therapy protocols have many time-sensitive details, and candidates under time pressure focus on the administered activity while skipping the safety checklist.
What to do instead
Use a pretherapy checklist: pregnancy test within the appropriate window, lactation status and cessation instructions, thyroid hormone withdrawal or rhTSH according to protocol, recent CBC and renal function, and dosimetry when indicated. State the check explicitly before selecting an activity.
In a high-acuity clinical stem, the candidate chooses a definitive nuclear medicine treatment or routine follow-up instead of immediate stabilization, source control, or holding the next therapy cycle.
Candidates prepare for nuclear medicine-specific facts and overlook acuity words, so they answer the long-term management question rather than the immediate next step.
What to do instead
Read the stem for acuity and time-horizon words such as 'next,' 'immediate,' 'unstable,' or 'febrile.' Triage immediate supportive care first, then select the nuclear medicine step. For therapy toxicity, know when to hold treatment, obtain cultures, or refer rather than proceeding with the next cycle.